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ORIGINAL ARTICLE
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ABSTRACT
Purpose: To find immunomediator combinations which could sensitively indicate keratoconus
progression.
Methods: Tear samples of 42 patients with keratoconus were collected at baseline and at the end of
a one-year follow-up. The concentrations of 13 mediators were measured by CBA. Based on Pentacam
HR examination, eyes were divided into a non-progressive and a progressive group.
Results: At the end of the follow-up, significant differences were observed in the release of IFNγ, IL-13,
IL-17A, CCL5, MMP-13 and PAI-1 between the two groups. Changes in five Pentacam parameters
correlated positively with changes in IFNγ, IL-13, IL-17A, CXCL8, CCL5, TIMP-1 and t-PA. We found that
tear level of IL-13 in combination with NGF can predict the progression of keratoconus with 100%
specificity and 80% sensitivity.
Conclusion: The findings of our longitudinal study may underscore the importance of NGF and IL-13
tear levels in the prediction of keratoconus progression.
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Keratoconus (KC) is a progressive ectatic corneal disorder
with heterogeneous clinical severity and varying
progression.12 Its prevalence is around 1:375 in the general
population highlighting its public health importance.3 The
etiology of this visually debilitating disease is not yet known
in detail, but recent studies suggest that the pathogenesis is
related to a combination of genetic, biomechanical, bio-
chemical and environmental risk factors including inflam-
mation, oxidative stress, and allergy.4–16
Altered levels of various cytokines, enzymes, regulatory
and growth factors, and diagnostic markers of inflammation
and tissue injury have been found in the tears or in the cornea
of patients with keratoconus, pointing to the crucial role of
the immune system in the pathogenesis of keratoconus.6,11–14
These include proinflammatory cytokines (tumor necrosis
factor (TNF), interleukin (IL)-1β, IL-6), inflammatory chemo-
kines (CXCL8, CCL5), inflammatory mediators (IL-12, inter-
feron (IFN)-γ, IL-17), the anti-inflammatory cytokine IL-10,
cytokines associated with allergy development (IL-4, IL-13),
enzymes and their co-factors associated with tissue remodel-
ing (matrix metalloproteinases (MMPs), tissue inhibitor of
metalloproteinase-1 (TIMP-1), cathepsin B). Various growth
factors, other enzymes, enzyme inhibitors, cellular proteins
which can serve as diagnostic markers in the context of
cellular and tissue injury or inflammation were also described,
including epidermal growth factor (EGF), vascular endothelial
growth factor (VEGF); insulin-growth factors (IGFs), nerve
growth factor (NGF), lipocalins, lipophilins, phospholipase
A2, cystatins, albumin, type I and type II keratins, lactoferrin,
Prolactin-Induced Protein, α-fibrinogen, α1-antitrypsin; apo-
lipoprotein A1 (ApoA1), lysozyme C, zinc-α2-glycoprotein
(ZAG), metabolic enzymes (e.g. GAPDH), different immuno-
globulins (IgA, IgG1, and the κ-isotype of the Ig light chains)
and the polymeric immunoglobulin transport receptor (pIgR/
PIGR).4–8,10−12,15–35 Disease specific changes in these molecu-
lar markers can be of diagnostic value in keratoconus.32
To the best of our knowledge, there are no studies exam-
ining these mediators in the tear fluid to predict the progres-
sion of the disease. However, early detection of progression in
keratoconus is of high importance because early identification
of the progressive nature of the disease allows early treatment
to reduce the risk of visual impairment. If tear biomarker
profiling could predict the progression of keratoconus earlier
than the parameters used nowadays, it would be ideal for
clinical application. Corneal collagen crosslinking (CXL)
proved to be effective in halting the progression of keratoco-
nus by several studies.36–39 It has been reported that the best
results of CXL are obtained in progressive KC patients treated
in early stage.40 This possible treatment underscores the chal-
lenge of identifying the appropriate patients as early as
possible.
In the present study, our goals were to determine the
concentrations of 13 different immune mediators in tear
samples of patients with keratoconus and to correlate the
changes of these mediators to the changes of Pentacam para-
meters which are used to detect progression. The tested multi-
functional mediators were chosen as representative molecules
that are associated with corneal degradation in KC. The
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MMP-9, MMP-13 are collagenases produced by various cell
types during tissue remodeling, involving injuries and tissue
repair. Their functions are regulated directly or indirectly by
inhibitors (e.g. TIMP-1) or activator proteases and their
respective activators and inhibitors (e.g. t-PA, plasminogen
activator inhibitor (PAI-1)). The other investigated mediators
are associated with different type of inflammatory processes
involving the Th1 or type 1 innate lymphoid cell (ILC1)
produced mediator: IFN-γ which take part in the classical
inflammatory macrophage activation. Pro-inflammatory cyto-
kines and chemokines produced by various innate inflamma-
tory cell types: IL-6, CXCL8/IL-8, CCL5/RANTES. Cytokines
mediating the resolution of the inflammation: IL-13, IL-10
produced by Th2 cells or ILC2 cells. IL-17α is an inflamma-
tory cytokine produced by Th17 cells or ILC3 cells normally
mediating neutrophil granulocyte rich inflammation and
other antimicrobial defense processes in the epithelial tissues.
NGF takes part in regulatory and healing mechanisms. Tear
immunomediator levels and Pentacam parameters were deter-
mined at baseline and at the end of the one-year follow-up
period. We aimed to find combinations of mediators which
can better predict the progression of the disease than single
mediators. The real clinical importance and relevance of our
study lies in its ability to tell from baseline mediator levels
whether keratoconus is likely to progress in the future. This
can lead to an earlier treatment of at-risk patients and there-
fore a better visual acuity preserved in these patients. To the
best of our knowledge, this is the first longitudinal study
evaluating mediators in order to predict the progression of
keratoconus.
Patients and Methods
Subjects and Clinical Examinations
We performed an observational cohort study involving well-
characterized keratoconus patients recruited from the
Department of Ophthalmology, Faculty of Medicine,
University of Debrecen, Hungary. Keratoconus was diagnosed
upon the presence of one or more of the following clinical
signs: central or paracentral stromal thinning of the cornea,
conical protrusion, Fleischer’s ring, Vogt’s striae by slit-lamp
examination, and topographic changes.41 Exclusion criteria
included the existence of active inflammatory or infectious
systemic or ocular disease (including atopic dermatitis), his-
tory of chronic, abnormal eye rubbing, and current treatment
with systemic or local anti-inflammatory drugs. Patients who
were pregnant or lactating during the course of the study and
eyes with a history of ocular surgery (including corneal cross-
linking) or trauma were also excluded. Altogether, 42 kerato-
conic patients (mean (SD) age 36.4 (12.3), range 15–68 years)
were enrolled in the study. Both eyes of each participant
underwent repeated ophthalmological evaluation, including
clinical history, automated kerato-refractometry (KR-8900;
Topcon Co, Tokyo, Japan), uncorrected and corrected dis-
tance visual acuity determinations, slit-lamp biomicroscopy
(under low illumination to avoid reflex tearing), Rotating
Scheimpflug tomography (Pentacam HR, Oculus Optikgeräte
GmbH, Wetzlar, Germany). Non-stimulated tear sample
collection with glass capillaries was performed at baseline
and at completion of a one-year follow-up period. We
involved only one eye of each patient at baseline that met all
inclusion but no exclusion criteria, except for patients with
one progressive and one non-progressive keratoconic eye, in
which case one eye was enrolled into the non-progressive, and
the other eye into the progressive group.
The study protocol was approved by the Regional and
Institutional Research Ethics Committee of the University of
Debrecen (DEOEC-RKEB/IKEB 3313–2011). Each patient
was informed of the nature of the study and gave informed
consent in writing. The tenets of the Declaration of Helsinki
were followed in all procedures during the study.
Pentacam Measurements
All eyes of the involved 42 keratoconus patients were exam-
ined with a Pentacam HR (Oculus GmBH, Wetzlar, software
version 1.16r26 and 1.17r139) without the application of any
eye drops at baseline and at the end of follow-up to determine
the progressive nature of the disease. Three sequential scans
were taken of each eye by the same trained examiner. The
detailed subscription of the method can be found in our
previous publication.31 The following parameters were
exported to Microsoft Excel (Microsoft Corp, Redmond,
Washington): Holladay equivalent keratometry values in the
flat (K1) and steep (K2) meridian; maximal keratometry of the
front surface (Kmax Front); corneal astigmatism of the front
surface (Astig); corneal thickness at the thinnest point of the
cornea (Pachy Min); Keratoconus Index (KI); Central
Keratoconus Index (CKI); and Belin-Ambrósio deviation
index (D-index). Keratoconus progression was defined as an
increase in K2 and/or Kmax and/or in astigmatism of 1.00
diopter (D) or more in the prior 12 months.41–44 Grade of KC
was defined as mild if the steepest keratometric reading K2
was <45 diopters, moderate if K2 was between 45 and 52D,
and severe if K2 was >52D.23
Tear Collection and Analysis
A detailed description of non-traumatic tear collection using
micro-capillary tubes from the inferior meniscus and the
handling of the samples can be found in our previous
publication.31 Tear collections were carried out at the same
time of the day, between 8.00 and 9.30 a.m. at the baseline
visit and at the end of the one-year follow-up. We calculated
tear volumes from the length of the tear column in the tube
on a micrometer scale.
The tear samples were analyzed for IL-6, IL-10, IL-13, IL-
17A, CXCL8/IL-8, CCL5/RANTES, IFN-gamma, MMP-9,
MMP-13, TIMP-1, NGF, t-PA, and PAI-1 concentrations
using the Cytometric Bead Array method. Combined
FlowCytomix Simplex Kits were used with the appropriate
FlowCytomix™ Basic Kit, with minor modifications to the
manufacturer’s instructions (eBioscience, Bender Med
Systems GmbH, Vienna, Austria). A detailed description can
be found in our previous publication.45 The subsequent detec-
tion limits were as follows: IL-6: 1.2 pg/ml; IL-10: 1.9 pg/ml;
IL-13: 4.5 pg/ml; IL-17A: 2.5 pg/ml; IFNγ: 1.6 pg/ml; CXCL8
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(IL-8): 0.5 pg/ml; CCL5 (RANTES): 25 pg/ml; MMP-9: 95 pg/
ml; MMP-13: 50 pg/ml; TIMP-1: 28 pg/ml; NGF: 126.8 pg/ml;
t-PA: 4.8 pg/ml; and PAI-1: 13.5 pg/ml.45
Statistical Analysis
If both eyes of the patient were in the same group, i.e. non-
progressive or progressive, then we only included one ran-
domly selected eye. Eye selection was based on generating
random values using Microsoft Excel set to produce numeric
indicators with equal probabilities for either eye. We included
automatically the fellow, keratoconic eye of the patient if the
other eye had a history of an invasive procedure (CXL, trans-
plantation) and was therefore subject to exclusion from the
study. We included both eyes if one was progressive and the
other was non-progressive in nature.
Mediator concentration and Pentacam parameter variables
were inspected for distribution shape and transformed to
improve normality if necessary. The quantities of mediators
released into tears were calculated using concentrations (pg/
μl) and tear volumes (μl) collected over 2 minutes.
First we analyzed the Pentacam data at baseline and end of
follow-up to determine the progression of the disease, and to be
able to classify the eyes of the 42 patients into two disease
groups, namely the non-progressive and the progressive groups.
Then we determined statistical correlations between the changes
in the levels of tear mediators and changes in Pentacam para-
meters during follow-up using linear regression.
As a third step, the predictive performance of tear fluid
mediators was evaluated using logistic regression. All possible
pairs of mediator concentration variables, and similarly of
release level variables, were formed and used as continuous
explanatory variables complete with an interaction term
between them, in models with observed progression as the
binary outcome. After each model fit, observations were sorted
on predicted probability and dichotomized for model diagnostic
purposes such that the number of predicted cases of progression
above the cut should equal the number of observed cases.
Observations with predicted probability of at least 50% were
used as predicted positives in evaluating the system for sensi-
tivity, specificity, and positive and negative predicted values
(PPV and NPV, respectively). For reference, the procedure
was repeated using Pentacam parameter pairs as explanatory
variables. Comparison was based on a non-parametric approach
evaluating the areas (AUC) under the receiver operating char-
acteristic curves (ROC) of each Pentacam parameter model
against those of each of the best two mediator release models.
For these models, cutoffs were not set on the measurement
scales of the predictor variables. Instead, model-predicted prob-
abilities greater than or equal to 50% were regarded as positive
predictions (progressive disease).
Results
Demographic and Pentacam Data at Baseline and End of
Follow-up
A total 45 eyes of 42 patients (mean (SD) age 36.4 (12.3), range
15–68 years) were enrolled in the study. At the end of follow-up,
eyes were classified into a non-progressive keratoconus group
(29 eyes) and a progressive keratoconus group (16 eyes) deter-
mined by Pentacam parameters. Generally, the study only
involved one eye of each patient, except in three patients
where one eye was in the non-progressive, and the other in
the progressive group. At baseline, KC grade in the non-
progressive vs progressive group was mild in 4 vs 0, moderate
in 18 vs 8, and severe in 7 vs 8 eyes. After one year, these counts
were 5 vs 0, 17 vs 8, and 7 vs 8, respectively.
Demographic and Pentacam data of patients in the non-
progressive and in the progressive keratoconus groups at base-
line and at the end of follow-up are presented in Tables 1 and 2.
At baseline, there were significant differences in K2 (p = .035),
Kmax (p = .014), D-index (p = .016) but not in any other
Pentacam values including astigmatism (p > .05). At the end of
follow-up, there were significant differences in K2 (p = .007),
Kmax (p = .0008), D-index (p = .0396) and also in corneal
astigmatism of the front surface (p = .027).
Tear Fluid Mediator Levels in the Two Groups during
Follow-up
At baseline, there were no significant differences between the
two groups in the release or concentration of mediators (all
p values>.05).
At the end of follow-up, there were significant differences
in the release of IFNγ, IL-13, IL-17A, CCL5, MMP-13, and
PAI-1 between the two groups (Table 3, Figure 1); however,
Table 1. Demographic and Pentacam data of participants at baseline.
Non-progressive keratoconus group (N = 29 eyes) Progressive keratoconus group (N = 16 eyes) p
Age (years) 37.3 (11.3) 33.5 (13.4) 0.386a,c
Sex (female/male) 11 (37%)/18 (63%) 4 (25%)/12 (75%) 0.728c
Follow-up time (days) 419 (352–1004) 418 (378–555) 0.610b
K1 44.9 (40.9–59.5) 46.6 (39.4–57.9) 0.302b
K2 48.9 (43.6–64.1) 51.7 (45.7–60.1) 0.035b
Kmax 52.9 (44.4–86.8) 59.4 (48.9–75.4) 0.014b
D-index 7.55 (4.17) 10.79 (4.14) 0.016a
Astig 3.57 (0.3–6.6) 4.65 (1.8–10.87) 0.055b
PachyMin 453 (288.3–534) 443.5 (332.7–560) 0.569b
KI 1.22 (0.15) 1.31 (0.14) 0.077a
CKI 1.03 (0.99–1.18) 1.08 (0.97–1.18) 0.117b
Significant differences are highlighted in bold; at test, values are presented as mean (SD); bWilcoxon’s rank-sum test, values are presented as p50 (min-max); cTest
excludes thee patients with eyes in both groups
Pentacam readings: K1 and K2, simulated keratometry 1 and 2 of the front surface (diopters); Kmax, maximal keratometry of the front surface; Astig, corneal
astigmatism of the front surface; PachyMin, thinnest corneal thickness; KI, keratoconus index; CKI, center keratoconus index.
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Figure 1. Significant (p value is <0.05) differences in released mediator quantities (pg) between the two groups at the end of follow-up eye counts are presented as
(n); INF?, interferon gamma; IL, interleukin; CCL5, chemokine (C–C motif) ligand 5 or RANTES (regulated on activation, normal T cell expressed and secreted); MMP-13,
matrix metalloproteinase-13; PAI-1, plasminogen activator inhibitor-1.
Table 2. Pentacam data of participants at end of follow-up.
Non-progressive keratoconus group (N = 29 eyes) Progressive keratoconus group (N = 16 eyes) p
K2 48.6 (43.6–61.9) 52.3 (46.2–61.2) 0.007b
Kmax 53.9 (6.1) 61.2 (7.2) 0.0008a
D-index 8.18 (4.81) 11.27 (4.44) 0.0396a
Astig 3.2 (0.6–5.9) 4.7 (0.5–12.3) 0.027b
PachyMin 453.7 (281–535.3) 441.3 (349–538.3) 0.538b
KI 1.23 (0.15) 1.31 (0.15) 0.109a
Significant differences are highlighted in bold; at test, values are presented as mean (SD); bWilcoxon’s rank-sum test, values are presented as p50 (min-max)
Pentacam readings: K2, simulated keratometry 2 of the front surface (diopters); Kmax, maximal keratometry of the front surface; Astig, corneal astigmatism of the
front surface; PachyMin, thinnest corneal thickness; KI, keratoconus index.
Table 3. Significant (p value is <0.05) differences in released mediator quantities (pg) between the two groups at the end of follow-up.
Non-progressive keratoconus group (N = 29 eyes) Progressive keratoconus group (N = 16 eyes) p
IFNγ 34.3 (0–179.9) (29) 60.6 (18.2–223.1) (13) 0.020 b
IL-13 21.0 (0–152.5) (29) 43.7 (6.1–171.3) (13) 0.018 b
IL-17A 36.9 (0.2–145.3) (29) 51.4 (15.3–197.8) (13) 0.022 b
CCL5/RANTES 2.71 (0.55–15.14) (18) 7.38 (0.94–23.62) (13) 0.041b
MMP-13 (log transformed) −0.40 (0.97) (26) 0.42 (1.33) (14) 0.031a
PAI-1 0.010 (0–0.200) (29) 0.043 (0.003–0.463) (15) 0.027b
at test, mean (SD), eye counts are presented as (n); bWilcoxon’s rank-sum test, p50 (min-max), eye counts are presented as (n).
IFNγ, gamma interferon; IL, interleukin; CCL5, chemokine (C–C motif) ligand 5 or RANTES (regulated on activation, normal T cell expressed and secreted); MMP-13,
matrix metalloproteinase-13; PAI-1, plasminogen activator inhibitor-1.
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no significant differences in mediator concentrations between
the two groups were observed.
Correlations between Changes in Tear Mediator Levels
and Changes in Pentacam Parameters during Follow-up
Significant differences were observed between the progressive
and the non-progressive group in the way changes in the
levels of the different tear mediators were correlated with
changes in Pentacam parameters, as shown in Table 4 and
Figures 2 and 3. Changes in five out of eight analyzed
Pentacam parameters correlated positively with changes in
IFNγ, IL-13, IL-17A, CXCL8, CCL5, TIMP-1, and t-PA.
Significance of Mediator Pairs in Tear Fluid in the
Prediction of Progressive Disease in Keratoconus
Of all possible baseline mediator pairings, those showing
reasonable predictive power for keratoconus progression
included IFNγ with NGF and IL-13 with NGF released
quantities.
High released levels of NGF, and moderately high levels of
NGF coupled with low levels of IFNγ or IL-13, were associated
with increased odds of progression. The plane defined by these
variable pairs was possible to separate, to a certain degree, into
non-progressive and a progressive area (Figure 4). The model
based on released quantities of IFNγ with NGF had a reasonable
specificity and NPV but a moderate sensitivity and PPV esti-
mate (ROC AUC = 0.9385), while the one based on released IL-
13 and NGF (AUC = 0.9692) had very high specificity and PPV
with high NPV and reasonable sensitivity (Table 5).
Pentacam Parameter Pairs in the Prediction of
Progressive Disease in Keratoconus
The predictive performance indicators of Pentacam parameter
pairs were similar to or poorer than (especially in relation to
IL-13 and NGF) those estimated for mediator release pairs
(Table 6). AUC values ranged from 0.3692 to 0.7385 and were
found significantly smaller in 40 out of 56 comparative rela-
tions with the two models based on mediator release.
Discussion
Several studies have revealed that inflammatory factors play
a key role in the pathomechanism of keratoconus and several
associations were revealed between the levels of inflammatory
mediators and the severity of the disease.10,28,29 Tear mediator
profile as a noninvasive biomarker of keratoconus can act as
a prognostic biomarker and may aid in the timely treatment
of this heterogeneous disease.6,32,34,46 To the best of our
knowledge, there is no longitudinal study evaluating media-
tors in order to predict the true progression of keratoconus.
The aim of this study was to determine mediators which
sensitively indicate keratoconus progression. The real clinical
importance and relevance of our study lies in the ability to tell
from current mediator levels whether keratoconus is likely to
progress in the future. This dictates an approach where base-
line levels, strictly without their follow-up counterparts, are
the explanatory variables and KC progression is a binary out-
come. Another interesting aspect is the possibility of interac-
tion between various mediators: it might be that no single
mediator is strongly predictive on its own, but a combination
where high levels of one are accompanied by low levels of
another is. Our findings suggest that certain mediators could
predict the progression of KC and have outstanding roles in
the pathomechanism of KC. Future directions may include
targeting these inflammatory factors in the management of
KC to restore the dysregulated inflammation in KC pathogen-
esis. This opens the potential to explore anti-inflammatory
strategies to either halt or delay the progression of KC.
In this study, first we evaluated the baseline concentrations
and release of mediators in the two patient groups (stable KC
eyes vs progressive KC eyes) and found no difference. Tear
fluid is easily accessible and may indicate the status of the
ocular surface; however, dynamic changes in the levels of
various mediators could also be related to the lacrimal gland
function. In our experience, even eyes suffering from the same
disease may produce variable amounts of tears within a set
sampling time, which is due to the large variations in indivi-
dual sensitivity and variability of the disease stages resulting in
various diluting effects. Differences in tear flow rate and
consequently in sample volumes must be taken into consid-
eration. Hence, we not only measured the concentrations of
mediators, but also calculated the rates of their release into
tears collected within 2 minutes.
Second, we analyzed the differences after one year and
found that there were significant differences between the
two groups in the release, but not the concentration, of
IFNγ, IL-13, IL-17A, CCL5, MMP-13 and PAI-1. This
means that not only the concentration itself but the amount
of the tear secretion changes with time and may have an
impact on the levels of mediators. It has to be later investi-
gated whether it is the inflammation generated by disease
progression that is responsible for an increase in tear produc-
tion or, alternatively, keratoconus is an essentially inflamma-
tory condition and it is the progression that generates an
increase in the production or release of different mediators.
Third, we presented positive correlations between molecu-
lar profiles and KC progression built on the differences
between two visits in the levels of mediators (IFNγ, IL-13,
IL-17A, CXCL8, CCL5, TIMP-1 and t-PA) and five Pentacam
parameters (K1, Kmax, Astig, KI, CKI). The change in astig-
matism and the KI correlates the strongest with mediator
changes, namely IFNγ, IL-13, IL-17A and CXCL8, CCL5,
and t-PA. In addition to K2, Kmax and D-index, astigmatism
was the parameter that changed significantly between the two
patient groups from baseline to the end of follow-up.
Interestingly, the increase in astigmatism during follow-up
correlates positively with the increase of three cytokines
(IFNγ, IL-13, IL-17A).
Fourth, in this study we revealed a significant role ofmediator
pairs in tears in the prediction of the progressive disease course
in keratoconus. As far as we know, this is the first study aiming at
the prediction of keratoconus with the help of tear mediators. In
our study, IFNγ with NGF and IL-13 with NGF released quan-
tities showed reasonable predictive power for keratoconus pro-
gression: high levels of NGF, and moderately high levels of NGF
OCULAR IMMUNOLOGY AND INFLAMMATION 5
Ta
bl
e
4.
Si
gn
ifi
ca
nt
,g
ro
up
w
is
e
he
te
ro
ge
ne
ou
s
co
rr
el
at
io
ns
be
tw
ee
n
ba
se
lin
e
to
fo
llo
w
-u
p
ch
an
ge
s
in
th
e
le
ve
ls
of
di
ffe
re
nt
te
ar
m
ed
ia
to
rs
an
d
ch
an
ge
s
in
Pe
nt
ac
am
pa
ra
m
et
er
s.
IN
Fγ
(p
g/
m
l)
IL
-1
3
(p
g/
m
l)
IL
-1
7A
(p
g/
m
l)
CX
CL
8/
IL
-8
(p
g/
m
l)
CC
L5
/R
AN
TE
S
(p
g/
m
l)
TI
M
P-
1
(n
g)
t-
PA
(p
g/
m
l)
no
n-
pr
og
pr
og
no
n-
pr
og
pr
og
no
n-
pr
og
pr
og
no
n-
pr
og
pr
og
no
n-
pr
og
pr
og
no
n-
pr
og
pr
og
no
n-
pr
og
pr
og
K1
r
=
0.
16
p
=
.4
7
r
=
0.
58
p
=
.0
5
*
p
=
.0
34
Km
ax
r
=
−
0.
25
p
=
.2
8
r
=
0.
55
p
=
.0
5
*
p
=
.0
13
As
tig
r
=
0.
20
p
=
.3
0
r
=
0.
57
p
=
.0
3
r
=
0.
27
p
=
.1
6
r
=
0.
57
p
=
.0
3
r
=
0.
13
p
=
.5
0
r
=
0.
70
p
=
.0
05
*
p
=
.0
17
p
=
.0
18
p
=
.0
01
KI
r
=
−
0.
08
p
=
.7
3
r
=
0.
68
p
=
.0
1
r
=
−
0.
04
p
=
.8
9
r
=
0.
64
p
=
.0
7
r
=
−
0.
30
p
=
.2
3
r
=
0.
54
p
=
.0
7
*
p
=
.0
15
p
=
.0
35
p
=
.0
20
CK
I
r
=
0.
23
p
=
.3
0
r
=
0.
63
p
=
.0
3
*
p
=
.0
21
*s
ig
ni
fic
an
t
di
ffe
re
nc
es
be
tw
ee
n
th
e
no
n-
pr
og
re
ss
iv
e
(n
=
29
ey
es
)
an
d
th
e
pr
og
re
ss
iv
e
(n
=
16
ey
es
)
gr
ou
p.
Te
ar
m
ed
ia
to
rs
(c
on
ce
nt
ra
ti
on
,
pg
/m
l):
IN
Fγ
,g
am
m
a
in
te
rf
er
on
;I
L,
In
te
rle
uk
in
;C
XC
L8
,c
he
m
ok
in
e
(C
-X
-C
m
ot
if)
lig
an
d
8
or
IL
-8
;C
CL
5,
ch
em
ok
in
e
(C
–C
m
ot
if)
lig
an
d
5
or
RA
N
TE
S
(r
eg
ul
at
ed
on
ac
tiv
at
io
n,
no
rm
al
T
ce
ll
ex
pr
es
se
d
an
d
se
cr
et
ed
);
t-
PA
,t
is
su
e
pl
as
m
in
og
en
ac
tiv
at
or
;t
ea
r
m
ed
ia
to
r
(r
el
ea
se
,
ng
):
TI
M
P-
1,
tis
su
e
in
hi
bi
to
r
of
m
et
al
lo
pr
ot
ei
na
se
-1
.
Pe
nt
ac
am
re
ad
in
gs
:K
1,
si
m
ul
at
ed
ke
ra
to
m
et
ry
1
of
th
e
fr
on
t
su
rf
ac
e;
Km
ax
,m
ax
im
al
ke
ra
to
m
et
ry
of
th
e
fr
on
t
su
rf
ac
e;
As
tig
,c
or
ne
al
as
tig
m
at
is
m
of
th
e
fr
on
t
su
rf
ac
e;
KI
,k
er
at
oc
on
us
in
de
x;
CK
I,
ce
nt
er
ke
ra
to
co
nu
s
in
de
x.
6 M. FODOR ET AL.
coupled with low IFNγ or IL-13 were associated with keratoco-
nus progression. Based on the models, prediction based on
released IL-13 and NGF seems to be more useful because it has
100% specificity and PPV with 93% NPV and reasonable (80%)
sensitivity (Table 5). Martínez-Abad et al47 designed a predictive
model for keratoconus progression based on refractive, topo-
graphic and aberrometric changes. Our findings suggest that
compared to Pentacam parameters, mediator release levels
might have at least similar, but potentially greater, predictive
power for keratoconus progression. This is to be fully clarified by
future research specifically targeted at the question.
Karaca et al48 used the serum neutrophil-to-lymphocyte
ratio (NLR) to predict keratoconus progression, based on its
predictive property of systemic inflammation in several dis-
eases. Although NLR is simple and inexpensive, it was found
to predict the presence of KC progression with only 79%
sensitivity and 81% specificity.48 We think that tear collection
is a non-traumatic and noninvasive procedure and tears can
truly reflect the local pathological disorders such as
keratoconus.
Based on the findings of our study, IFNγ, IL-13, IL-17A,
CXCL8, CCL5, MMP-13, TIMP-1 t-PA, PAI-1 and NGF seem
Figure 2. Significant, groupwise heterogeneous correlations between baseline to follow-up changes in the levels of interleukin-17 (IL-17/A) concentration (pg/ml)
and changes in corneal astigmatism of the front surface (Astig F) measured with Pentacam between the non-progressive (n=29 eyes) and the progressive (n=16
eyes) group (one representative example of Table 4 for significant correlation).
Figure 3. Non-significant correlation between baseline to follow-up changes in the levels of interleukin-8 (IL-8) concentration (pg/ml) and changes in corneal
astigmatism of the front surface (Astig F) measured with Pentacam between the non-progressive (n=20 eyes) and the progressive (n=13 eyes) group (one
representative example of Table 4 for non-significant correlation).
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to have a crucial function in the progression of keratoconus;
as to prediction, IL-13 and NGF have the most important
role. We found a significant positive association in tears of
patients with KC between CCL5, MMP-13 and NGF levels
and several topographic data and showed that IL-13, CXCL8,
CCL5 and MMP-13 have different effects on the severity of
Figure 4. Logistic regression-predicted and observed progression of keratoconus in relation to baseline released quantities of tear mediator pairs (INF?+NGF, IL-13
+NGF). Curves indicate model-derived location of probability threshold ensuring equal number of predicted and observed progressive cases. INF?, gamma interferon;
IL-13, interleukin-13; NGF, nerve growth factor.
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disease depending on age.28 Age influences the immune
response and also the progressive nature of keratoconus. We
revealed significant differences in the release of IL-13, CCL5,
MMP-13 and also IFNγ, IL-17A and PAI-1 between the two
groups showing their pivotal role not only in the pathome-
chanism of KC but in the course of progression. Produced by
Th1 cells, IFNγ is associated with autoinflammatory and
autoimmune diseases. Increased IL-13 and IFNγ concentra-
tions were measured in the tears of KC patients.29,30 Patients
with keratoconus had significantly higher levels of IFNγ
(mean: 33.3 (SD 7.6) pg/ml) compared with control subjects
(mean: 23.0 (SD 4.7) pg/ml) (P = .0001), without making any
correction with tear flow rate, which is in line with our
concentration levels (mean: 38.7 (SD 23.9) pg/ml) in the non-
progressive group and 43.6 (SD 4.8) pg/ml in the progressive
group at the end of the follow-up).29 Jun et al23 showed
significantly increased tear levels of IL-17 and decreased IL-
13 and CCL5 in keratoconus compared to normal controls.
IL-17 is the principal proinflammatory cytokine produced by
T helper 17 cells and is associated with many chronic inflam-
matory conditions.14 Based on our study IFNγ with NGF and
IL-13 with NGF are predictive indicators of keratoconus
progression. IFNγ has a broad range of biological functions
and IL-13 is produced by Th2 cells, as IL-10. IL-13 plays
crucial roles in amplification of the Th2 response which is
dampened in keratoconus. The contrary is found in allergic
conjunctivitis or vernal and atopic keratoconjunctivitis.23
Balasubramanian et al26 detected increased expression of IL-
10 and IL-6 and classified keratoconus as an inflammatory
disease. Interestingly, we could not reveal any differences in
the tear levels of IL-6 or IL-10 between the progressive and
non-progressive groups, although Lema et al4,5 observed
increased levels of IL-6, while Sorkhabi et al29 measured
decreased levels of IL-10 in keratoconic tears. IL-6 increases
chemokine activation, including CXCL8 (which was higher in
our study in the progressive group), and IL-10 inhibits IL-6.
These results suggest that because of cytokine interaction,
many of them have a role in the pathomechanism but are
less significantly involved in the progression and only some
mediators can be used as progression predictors. The goal of
our study is to identify some of these biomarkers that con-
tribute to KC progression in order to recognize the progres-
sion of this visually debilitating disease earlier. Higher levels
of NGF existing in tears of patients with progressive
Table 5. Diagnostic performance indicators of pairs of baseline tear mediator release levels in predicting keratoconus progression.
Sensitivity 95%CI Specificity 95%CI
PPV (%)
95%CI
NPV (%)
95%CI p value of the model
INFγ and NGF 60%
(14.7–94.7)
84.6 % (54.6–98.1) 60%
(14.7–94.7)
84.6 % (54.6–98.1) 0.0058
IL-13 and NGF 80%
(28.4–99.5)
100%
(75.3–100)
100%
(39.8–100)
92.9 %
(66.1–99.8)
0.0008
Tear mediators (release (pg), square root transformed): IFNγ, gamma interferon; IL-13 = interleukin-13; NGF, nerve growth factor; PPV, positive predictive value; NPV,
negative predictive value.
Table 6. Diagnostic performance indicators of pairs of baseline Pentacam data to predict keratoconus progression.
Sensitivity 95%CI Specificity 95%CI
PPV (%)
95%CI
NPV (%)
95%CI p value of the model
Astig and CKI 38% (15–65) 86% (68–96) 60% (26–88) 71% (54–85) 0.003
Astig and D-index 38% (15–65) 90% (73–98) 67% (30–93) 72% (55–86) 0.002
Astig and K1 38% (15–65) 86% (68–96) 60% (26–88) 71% (54–85) 0.007
Astig and K2 44% (20–70) 83% (64–94) 58% (28–85) 73% (55–87) 0.024
Astig and KI 44% (20–70) 90% (73–98) 70% (35–93) 74% (57–88) 0.011
Astig and Kmax 50% (25–75) 86% (68–96) 67% (35–90) 76% (58–89) 0.005
Astig and Pachy Min 19% (4–46) 93% (77–99) 60% (15–95) 68% (51–81) 0.014
CKI and D-index 25% (7–52) 86% (68–96) 50% (16–84) 68% (50–82) 0.113
CKI and K1 31% (11–59) 90% (73–98) 63% (25–92) 70% (53–84) 0.237
CKI and K2 31% (11–59) 86% (68–96) 56% (21–86) 69% (52–84) 0.298
CKI and KI 31% (11–59) 93% (77–99) 71% (29–96) 71% (54–85) 0.259
CKI and Kmax 44% (20–70) 90% (73–98) 70% (35–93) 74% (57–88) 0.089
CKI and Pachy Min 38% (15–65) 90% (73–98) 67% (30–93) 72% (55–86) 0.126
D-index and K1 31% (11–59) 86% (68–96) 56% (21–86) 69% (52–84) 0.077
D-index and K2 63% (35–85) 83% (64–94) 67% (38–88) 80% (61–92) 0.063
D-index and KI 25% (7–52) 83% (64–94) 44% (14–79) 67% (49–81) 0.098
D-index and Kmax 44% (20–70) 86% (68–96) 64% (31–89) 74% (56–87) 0.089
D-index and Pachy Min 56% (30–80) 83% (64–94) 64% (35–87) 77% (59–90) 0.001
K1 and K2 38% (15–65) 86% (68–96) 60% (26–88) 71% (54–85) 0.068
K1 and KI 25% (7–52) 93% (77–99) 67% (22–96) 69% (52–83) 0.355
K1 and Kmax 44% (20–70) 83% (64–94) 58% (28–85) 73% (55–87) 0.030
K1 and Pachy Min 6 % (0–30) 100% (88–100) 100% (3–100) 66% (50–80) 0.745
K2 and KI 44% (20–70) 90% (73–98) 70% (35–93) 74% (57–88) 0.190
K2 and Kmax 69% (41–89) 76% (57–90) 61% (36–83) 82% (62–94) 0.037
K2 and Pachy Min 44% (20–70) 83% (64–94) 58% (28–85) 73% (55–87) 0.040
KI and Kmax 25% (7–52) 93% (77–99) 67% (22–96) 69% (52–83) 0.164
KI and Pachy Min 25% (7–52) 86% (68–96) 50% (16–84) 68% (50–82) 0.175
Kmax and Pachy Min 56% (30–80) 83% (64–94) 64% (35–87) 77% (59–90) 0.002
PPV, positive predictive value; NPV, negative predictive value. Pentacam readings: K1 and K2, simulated keratometry 1and 2 of the front surface; Kmax, maximal
keratometry of the front surface; Astig, corneal astigmatism of the front surface; KI, keratoconus index; CKI, center keratoconus index; PachyMin, thinnest corneal
thickness.
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keratoconus is in line with the well-known neural sensitizing
role of this neuromediator.49 In our previous study we
revealed not only disease specific mediators in the tear fluid
of patients, but we confirmed several associations between the
levels of mediators and the severity of keratoconus, including
NGF.28 Lacrimal glands are known to produce, release, and be
responsive to NGF, and NGF is a normal constituent of the
tear film.50 Correlation between NGF tear levels and the
severity of corneal damage in the tear film of patients with
dry eye disease was established51; moreover, NGF promotes
corneal healing in physiologic and pathologic conditions, and
it has been shown that corneal injuries induce an increase in
local NGF and NGF receptors capable of stimulating epithelial
healing.52 These observations suggest that NGF may be
involved in local tissue damage. The inadequate balance
between pro-inflammatory cytokines, proteolytic enzymes,
protease inhibitors, inflammatory modulators and antioxi-
dants may lead to increased activity of metalloproteinases.10
Several studies have investigated the role of proteolytic
enzymes such as MMPs in KC. MMPs are involved in the
degradation of extracellular matrix or activation of cellular
apoptosis. In keratoconus, the cornea expresses elevated levels
of MMP-13 and the levels of MMP-1, -3, -7 and MMP-13 are
also increased in the tear fluid.19,26 The enzymatic activity of
MMPs depends on TIMP, which is a potent inhibitor of
MMPs. Pouliquen et al53 suggested that cytokines, including
CXCL8, might regulate the protease cascade including the
plasmin system, involving t-PA and PAI, and also MMPs,
which would lead to extracellular matrix changes in
keratoconus.
Since keratoconus progression results in severe irreversi-
ble loss of visual acuity, it indicates a relevant need to find
biomarkers which promptly and sensitively indicate disease
progression in the future in order to select the progressive
forms in time for CXL treatment.47 The limitations of this
study are that it cannot exclude the possibility of other
mediators being involved in the progression of the kerato-
conic cornea, and that the identification of the source and
activity of the mediators has not been investigated. Tear
samples are crucial in understanding the molecular mechan-
ism of the progression process and the multiplex platform is
perfectly suited for the detection of biomarkers from tear
samples. Ideally, because the progression of the disease will
stop at a point, which can be accompanied by an alteration
in mediator levels including a decrease of IL-13/NGF, it
would have been useful to monitor the tears of eyes with
progressive keratoconus without any treatment for a longer
time to find out about the time of progression arrest; how-
ever, in this study the vast majority of the eyes with pro-
gressive keratoconus needed and received CXL treatment,
making such long-term observations largely unavailable.
Despite these limitations, it is important to indicate that
our results underline the fact that many mediators are
involved in the complex mechanisms of keratoconus pro-
gression. It remains to be determined in further studies
which of these mediators or any others are principal in
predicting keratoconus progression.
To conclude, our study confirms that different mediators
in the tear fluid could predict the progression of
keratoconus and may underscore the important roles of
NGF and IL-13, which together seem to be useful in the
prediction of the progression with 100% specificity and
PPV, 93% NPV, and 80% sensitivity. Locally released med-
iators serve as additional proof for considering corneal
cross-linking treatment in an attempt to stop KC progres-
sion. As next steps, the critical levels of these mediators and
the precise roles of the identified predictive biomarkers need
to be defined on a larger cohort to reveal their potential use
not only as diagnostic markers but as therapeutic targets as
well. The potential roles of biomarkers include being com-
ponents in a KC progression predictive system combined
with other input variables such as Pentacam parameters,
age, or other data available in a real-life clinical setting.
Disclosure of interest
No potential conflict of interest was reported by the authors.
The data that support the findings of this study are available from the
corresponding author, [MF], upon reasonable request.
Funding
No financial support was received for this submission.
ORCID
Mariann Fodor http://orcid.org/0000-0002-1089-3899
Géza Vitályos http://orcid.org/0000-0001-9139-3572
Gergely Losonczy http://orcid.org/0000-0002-9332-1457
Ziad Hassan http://orcid.org/0000-0001-5070-1233
Dorottya Pásztor http://orcid.org/0000-0002-1390-0548
Péter Gogolák http://orcid.org/0000-0001-9411-9587
Bence Lajos Kolozsvári http://orcid.org/0000-0002-1517-8157
References
1. Krachmer JH, Eagle RC, Belin MD. Keratoconus and related
non-inflammatory corneal thinning disorders. Surv Ophthalmol.
1984;28:293–322. doi:10.1016/0039-6257(84)90094-8.
2. Rabinowitz YS. Keratoconus. Surv Ophthalmol. 1998;42:297–319.
doi:10.1016/S0039-6257(97)00119-7.
3. Godefrooij DA, de Wit GA, Uiterwaal CS, Imhof SM, Wisse RP,
Incidence A-S. Prevalence of Keratoconus: A nationwide registra-
tion study. Am J Ophthalmol. 2017;175:169–172. doi:10.1016/j.
ajo.2016.12.015.
4. Lema I, Duran JA. Inflammatory molecules in the tears of patients
with keratoconus. Ophthalmology. 2005;112:654–659. doi:10.1016/
j.ophtha.2004.11.050.
5. Lema I, Sobrino T, Duran JA, Brea D, Diez-Feijoo E. Subclinical
keratoconus and inflammatory molecules from tears. British
J Ophthalmol. 2009;93:820–824. doi:10.1136/bjo.2008.144253.
6. Ionescu C, Corbu CG, Tanase C, et al. Inflammatory biomarkers
profile as microenvironmental expression in Keratoconus. Dis
Markers. 2016;2016:1243819. doi:10.1155/2016/1243819.
7. Kenney MC, Chwa M, Atilano SR, et al. Increased levels of
catalase and cathepsin V/L2 but decreased TIMP-1 in keratoconus
corneas: evidence that oxidative stress plays a role in this disorder.
Invest Ophthalmol Vis Sci. 2015;46:823–832. doi:10.1167/iovs.04-
0549.
8. Balasubramanian SA, Wasinger VC, Pye DC, Willcox MD.
Preliminary identification of differentially expressed tear proteins
in keratoconus. Mol Vis. 2013;19:e2124–34.
10 M. FODOR ET AL.
9. Gordon-Shaag A, Millodot M, Shneor E, Liu Y. The genetic and
environmental factors for keratoconus. Biomed Res Int.
2015;2015:795738. doi:10.1155/2015/795738.
10. Galvis V, Sherwin T, Tello A, Merayo J, Barrera R, Acera A.
Keratoconus: an inflammatory disorder? Eye. 2015;29:843–885.
doi:10.1038/eye.2015.63.
11. Yenihayat F, Ö A, Kasap M, Akpınar G, Güzel N, Çelik OS.
Comparative proteome analysis of the tear samples in patients
with low-grade keratoconus. Int Ophthalmol. 2018;38
(5):1895–1905. doi:10.1007/s10792-017-0672-6.
12. McKay TB, Hjortdal J, Priyadarsini S, Karamichos D. Acute
hypoxia influences collagen and matrix metalloproteinase expres-
sion by human keratoconus cells in vitro. PLoS One. 2017;2017:
e0176017. doi:10.1371/journal.pone.0176017.
13. McKay TB, Hjortdal J, Sejersen H, Karamichos D. Differential
effects of hormones on cellular metabolism in Keratoconus in
vitro. Sci Rep. 2017;17:42896. doi:10.1038/srep42896.
14. Wisse RP, Kuiper JJ, Gans R, Imhof S, Radstake TR, Van der
Lelij A. Cytokine expression in keratoconus and its corneal micro-
environment: A systematic review. Ocul Surf. 2015;13:272–283.
doi:10.1016/j.jtos.2015.04.006.
15. Yuksel E, Yalinbas D, Aydin B, Bilgihan K. Keratoconus progres-
sion induced by in vitro fertilization treatment. J Refract Surg.
2016;32:60–63. doi:10.3928/1081597X-20151207-10.
16. Shen Y, Han T, Jhanji V, et al. Correlation between corneal
topographic, densitometry, and biomechanical parameters in
Keratoconus eyes. Transl Vis Sci Technol. 2019;6;8:12.
doi:10.1167/tvst.8.3.12.
17. Collier SA. Is the corneal degradation in keratoconus caused by
matrix-metalloproteinases? Clin Exp Ophthalmol.
2001;29:340–344. doi:10.1046/j.1442-9071.2001.d01-17.x.
18. Saghizadeh M, Chwa M, Aoki A, et al. Altered expression of
growth factors and cytokines in Keratoconus, bullous keratopathy
and diabetic corneas. Exp Eye Res. 2001;73:179–189. doi:10.1006/
exer.2001.1028.
19. Mackiewicz Z, Määttä M, Stenman M, Konttinen L, Tervo T,
Konttinen YT. Collagenolytic proteinases in keratoconus. Cornea.
2006;25:603–610. doi:10.1097/01.ico.0000208820.32614.00.
20. Matthews FJ, Cook SD, Majid MA, Dick AD, Smith VA. Changes in
the balance of the tissue inhibitor of matrix metalloproteinases
(TIMPs)-1 and −3 may promote keratocyte apoptosis in keratoconus.
Exp Eye Res. 2007;84:1125–1134. doi:10.1016/j.exer.2007.02.013.
21. Lema I, Brea D, Rodríguez-González R, Díez-Feijoo E, Sobrino T.
Proteomic analysis of the tear film in patients with keratoconus.
Mol Vis. 2010;16:2055–2061.
22. Pannebaker C, Chandler HL, Nichols JJ. Tear proteomics in
keratoconus. Mol Vis. 2010;16:1949–1957.
23. Jun AS, Cope L, Speck C, et al. Subnormal cytokine profile in the
tear fluid of keratoconus patients. PLoS One. 2011;6:e16437.
doi:10.1371/journal.pone.0016437.
24. Acera A, Vecino E, Rodríguez-Agirretxe I, et al. Changes in tear
protein profile in keratoconus disease. Eye. 2011;25:1225–1233.
doi:10.1038/eye.2011.105.
25. Sakimoto T, Sawa M. Metalloproteinases in corneal diseases:
degradation and processing. Cornea. 2012;31(Suppl1):S50–6.
doi:10.1097/ICO.0b013e318269ccd0.
26. Balasubramanian SA, Mohan S, Pye DC, Willcox MD. Proteases,
proteolysis and inflammatory molecules in the tears of people
with keratoconus. Acta Ophthalmol. 2012;90:e303–e309.
doi:10.1111/j.1755-3768.2011.02369.x.
27. Balasubramanian SA, Pye DC, Willcox MD. Levels of lactoferrin,
secretory IgA and serum albumin in the tear film of people with
keratoconus. Exp Eye Res. 2012;96:132–137. doi:10.1016/j.
exer.2011.12.010.
28. Kolozsvári BL, Petrovski G, Gogolák P, et al. Association between
mediators in the tear fluid and the severity of keratoconus.
Ophthalmic Res. 2014;51:46–51. doi:10.1159/000351626.
29. Sorkhabi R, Ghorbanihaghjo A, Taheri N, Ahoor MH. Tear film
inflammatory mediators in patients with keratoconus.
Int Ophthalmol. 2015;35:467–472. doi:10.1007/s10792-014-9971-3.
30. Shetty R, Ghosh A, Lim RR, et al. Elevated expression of matrix
metalloproteinase-9 and inflammatory cytokines in keratoconus
patients is inhibited by cyclosporine A. Invest Ophthalmol Vis Sci.
2015;56:738–750. doi:10.1167/iovs.14-14831.
31. Pásztor D, Kolozsvári BL, Csutak A, et al. Scheimpflug imaging
parameters associated with tear mediators and bronchial asthma
in Keratoconus. J Ophthalmol. 2016;2016:e9392640.
32. Nishtala K, Pahuja N, Shetty R, Nuijts RM, Ghosh A. Tear
biomarkers for keratoconus. Eye Vis (Lond). 2016;3:e19. 4.
doi:10.1186/s40662-016-0051-9.
33. Shetty R, Deshmukh R, Ghosh A, Sethu S, Jayadev C. Altered tear
inflammatory profile in Indian keratoconus patients - the 2015 col
rangachari award paper. Indian J Ophthalmol. 2017;65:1105–1108.
doi:10.1016/j.jcrs.2011.08.041.
34. Sharif R, Bak-Nielsen S, Hjortdal J, Karamichos D. Pathogenesis
of Keratoconus: The intriguing therapeutic potential of
Prolactin-inducible protein. Prog Retin Eye Res. 2018;67:150–167.
doi:10.1016/j.preteyeres.2018.05.002.
35. Sharif R, Bak-Nielsen S, Sejersen H, Ding K, Hjortdal J,
Karamichos D. Prolactin-Induced Protein is a novel biomarker
for Keratoconus. Exp Eye Res. 2019;179:55–63. doi:10.1016/j.
exer.2018.10.015.
36. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-a-induced col-
lagen crosslinking for the treatment of keratoconus.Am J Ophthalmol.
2003;135:620–627. doi:10.1016/S0002-9394(02)02220-1.
37. Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen cross-
linking with riboflavin and ultraviolet-A light in keratoconus:
long-term results. J Cataract Refract Surg. 2008;34:796–801.
doi:10.1016/j.jcrs.2007.12.039.
38. Vinciguerra P, Albè E, Trazza S, Seiler T, Epstein D.
Intraoperative and postoperative effects of corneal collagen
cross-linking on progressive keratoconus. Arch Ophthalmol.
2009;127:1258–1265. doi:10.1001/archophthalmol.2009.205.
39. Greenstein SA, Fry KL, Hersh MJ, Hersh PS. Higher-order aber-
rations after corneal collagen crosslinking for keratoconus and
corneal ectasia. J Cataract Refract Surg. 2012;38:292–302.
doi:10.1016/j.jcrs.2011.08.041.
40. Arora R, Jain P, Goyal JL, Gupta D. Comparative analysis of
refractive and topographic changes in early and advanced
Keratoconic eyes undergoing corneal collagen crosslinking.
Cornea. 2013;32:1359–1364. doi:10.1097/ICO.0b013e3182a02ddb.
41. Rabinowitz YS. Videokeratographic indices to aid in screening for
keratoconus. J Refract Surg. 1995;11:371–379.
42. De Bernardo M, Capasso L, Lanza M, et al. Long-term results of
corneal collagen crosslinking for progressive keratoconus.
J Optom. 2015;8:180–186. doi:10.1016/j.optom.2014.05.006.
43. Spadea L, Salvatore S, Verboschi F, Vingolo EM. Corneal collagen
cross-linking followed by phacoemulsification with IOL implanta-
tion for progressive keratoconus associated with high myopia and
cataract. Int Ophthalmol. 2015;35:727–731. doi:10.1007/s10792-
015-0107-1.
44. Waszczykowska A, Jurowski P. Two-year accelerated corneal
cross-linking outcome in patients with progressive keratoconus.
Biomed Res Int. 2015;2015:325157.
45. Fodor M, Kolozsvári BL, Petrovski G, et al. Effect of contact lens
wear on the release of tear mediators in keratoconus. Eye Contact
Lens. 2013;39:147–152. doi:10.1097/ICL.0b013e318273b35f.
46. Wei Y, Gadaria-Rathod N, Epstein S, Asbell P. Tear cytokine
profile as a noninvasive biomarker of inflammation for ocular
surface diseases: standard operating procedures. Invest
Ophthalmol Vis Sci. 2013;54:8327–8336. doi:10.1167/iovs.13-12132.
47. Martínez-Abad A, Piñero DP, Chorro E, Bataille L, Alió JL.
Development of a reference model for Keratoconus progression
prediction based on characterization of the course of nonsurgi-
cally treated cases. Cornea. 2018;37:1497–1505. doi:10.1097/
ICO.0000000000001673.
48. Karaca EE, Özmen MC, Ekici F, Yüksel E, Türkoğlu Z.
Neutrophil-to-lymphocyte ratio may predict progression in
patients with keratoconus. Cornea. 2014;33:1168–1173.
doi:10.1097/ICO.0000000000000260.
OCULAR IMMUNOLOGY AND INFLAMMATION 11
49. Lee HK, Lee KS, Kim HC, Lee SH, Kim EK. Nerve growth factor
concentration and implications in photorefractive keratectomy vs
laser in situ keratomileusis. Am J Ophthalmol. 2005;139:965–971.
doi:10.1016/j.ajo.2004.12.051.
50. Nguyen DH, Beuerman RW, Thompson HW, DiLoreto DA.
Growth factor and neurotrophic factor mRNA in human lacrimal
gland. Cornea. 1997;16:192–199.
51. Lambiase A, Micera A, Sacchetti M, Cortes M, Mantelli F,
Bonini S. Alterations of tear neuromediators in dry eye disease.
Arch Ophthalmol. 2011;129:981–986. doi:10.1001/
archophthalmol.2011.200.
52. Lambiase A, Manni L, Bonini S, Rama P, Micera A, Aloe L. Nerve
growth factor promotes corneal healing: structural, biochemical,
and molecular analyses of rat and human corneas. Invest
Ophthalmol Vis Sci. 2000;41:1063–1069.
53. Pouliquen Y, Bureau J, Mirshahi M, Mirshahi SS, Assouline M,
Lorens G. Keratoconus and inflammatory processes. Bull Soc Belge
Ophtalmol. 1996;262:25–28.
12 M. FODOR ET AL.
